TABLE 1.

Showing baseline and 1st year follow‐up characteristics as well as the immunotherapy during the first year after diagnosis

Cohort (n = 194)	Mean/Proportion	95% confidence interval	Range
Sex (female, n [%])	114/194 (58.8%)	.	.
Age at diagnosis (years)	34.9	33.3–36.5	15–69
EDSS score at baseline	1.8	1.6–1.9	0–3.5
Time between first symptoms and diagnosis (month)	22.3	15.7–28.8	0–358
Observation time (month)	78.3	72.6–84.0	20–204
Number of relapses in the 1st year of diagnosis	0.4	0.3–0. 5	0–4
Number of Gadolinium‐enhancing lesions on the MRI 12 months (+/‐ 3 months)	0.7	0.3–1.1	0–30
Number of T2‐ hyperintense lesions on the MRI 12 months (+/‐ 3 months)	2.2	1.6–2.7	0–29
1st year immunotherapy:		.	.
Interferon beta	89/163 (54.6%)	.	.
Glatiramer acetate	14/163 (8.6%)	.	.
Fingolimod	21/163 (12.9%)	.	.
Dimethyl fumarate	25/163 (15.3%)	.	.
Teriflunomide	1/163 (0.6%)	.	.
Natalizumab	12/163 (7.4%)	.	.
Ocrelizumab	1/163 (0.6%)	.	.
Immunotherapies changes (n, [%])
	Not changed compared to 1st immunotherapy	59/163 (36.2%)	.
	Treatment intensification	58/163 (35.6%)	.
	“Lateral shift”	43/163 (25.8%)	.
	Treatment de‐escalation	4/163 (2.5%)	.

Changes in immunotherapies based on the EMA 1st and 2nd line therapies are displayed, “lateral shift” represents a change in immunotherapy within EMA 1st or 2nd line therapies.

Abbreviation: EDSS, extended disability status scale, EMA, European Medical Agency.